Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Plasbumin-25 Market Size And Revenue Outlook Through 2030
Over the historical timeframe, growth was largely a consequence of its consistent utilization in cases of shock and hypovolemia. Additional contributing elements included the expansion of critical care medicine, increased dependence on plasma albumin therapies, a rise in surgical procedures, and the formal adoption within hospital protocols.
The anticipated expansion during the forecast period is due to an increase in the occurrence of liver diseases, a rise in intensive care unit admissions, an uptick in burn and trauma incidents, the development of hospital facilities, and a consistent need for plasma proteins.
Key developments expected during the forecast period involve the widespread application of concentrated albumin solutions, an increasing requirement in managing critical care, a strong preference for volume expansion treatments, an expansion in surgical and ICU uses, and ongoing dependence on proteins derived from plasma.
Get A Free Sample Report With In-Depth Market Insights:
Plasbumin-25 Market Growth Backed By Core Demand Fundamentals
The escalating prevalence of liver disorders is anticipated to fuel the expansion of the plasbumin-25 market. Liver disorders encompass various conditions that compromise the liver’s proper functioning, including cirrhosis, hepatitis, fatty liver disease, and liver cancer. The growing incidence of these conditions is attributed to factors such as increased alcohol consumption, obesity, diabetes, and viral infections like hepatitis. Plasbumin-25 is utilized in liver diseases to re-establish albumin levels in conditions such as cirrhosis, hepatic failure, and ascites, assisting in fluid balance management and preventing complications. For instance, in April 2024, the Office for Health Improvement and Disparities, a UK-based government body, reported that hospital admissions for liver disease in England increased to 85,665, corresponding to a directly standardized rate of 155.2 per 100,000 population, indicating a rise compared with previous years. Admissions solely due to alcoholic liver disease amounted to 27,085, emphasizing a persistent increase in alcohol-related liver complications. Thus, the escalating prevalence of liver disorders is a key driver for the plasbumin-25 market growth. The rising count of deaths from road accidents is projected to boost the plasbumin-25 market’s expansion. Road fatalities refer to deaths directly resulting from injuries acquired in traffic collisions or road-related incidents. The surge in such fatalities is linked to factors like elevated vehicle speeds, driver distraction from mobile phones, and inadequate road safety provisions. Furthermore, increasing urbanization and a greater volume of vehicles on roads lead to more frequent and serious traffic incidents. Plasbumin-25 is commonly employed for managing hypovolemic shock stemming from accidents like vehicle collisions, severe burns, or trauma, characterized by considerable blood or fluid loss. For example, data from February 2023, compiled by Statistisches Bundesamt, a German federal statistical agency, indicated that around 21,600 people sustained injuries in road traffic in 2023, representing an increase of about 900 injuries, or 5%, compared to 2022. Moreover, the death toll from traffic accidents climbed by 13, reaching a total of 167 in February 2023. Consequently, the growing incidence of road fatalities will propel the plasbumin-25 market.
Plasbumin-25 Market Segment Performance And Emerging Opportunities
The plasbumin-25 market covered in this report is segmented –
1) By Packaging Size: 50 mL, 250 mL, 500 mL
2) By Indication: Hypovolemic Shock, Hypoproteinemia, Acute Respiratory Distress Syndrome (ARDS), Cardiopulmonary Bypass, Acute Liver Failure
3) By Distribution Channel: Hospitals And Clinics, Retail And Specialty Pharmacies
4) By End User: Adult Patients, Geriatric Patients
Plasbumin-25 Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the plasbumin-25 market are Grifols S.A.
View The Full Plasbumin-25 Market Report:
Plasbumin-25 Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the plasbumin-25 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasbumin-25 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
